Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Navepegritide: First Approval.

Drugs·2026
Same author

Pixavir Marboxil: First Approval.

Drugs·2026
Same author

Deciphering the Transcription Factor Landscape in Prostate Cancer Progression: A Novel Approach to Understand NE Transdifferentiation.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2025
Same author

Correction: Donanemab: First Approval.

Drugs·2024
Same author

Donanemab: First Approval.

Drugs·2024
Same author

Sotatercept: First Approval.

Drugs·2024

Related Experiment Video

Updated: Jul 14, 2025

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

7.7K

Avacincaptad Pegol: First Approval.

Connie Kang1

  • 1Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. dru@adis.com.

Drugs
|October 9, 2023
PubMed
Summary

Avacincaptad pegol, a complement C5 inhibitor, is now approved for treating geographic atrophy secondary to age-related macular degeneration. This marks a significant milestone in the development of therapies for this advanced eye condition.

Area of Science:

  • Ophthalmology
  • Immunology
  • Pharmacology

Background:

  • Geographic atrophy (GA) secondary to age-related macular degeneration (AMD) is a leading cause of irreversible vision loss.
  • Current treatment options for GA are limited, highlighting the need for effective therapeutic interventions.
  • Complement system dysregulation, particularly involving complement C5, is implicated in the pathogenesis of GA.

Purpose of the Study:

  • To summarize the key developmental milestones of avacincaptad pegol.
  • To highlight the journey leading to the recent approval of avacincaptad pegol for GA secondary to AMD.
  • To provide an overview of avacincaptad pegol as a novel therapeutic agent.

Main Methods:

  • Avacincaptad pegol is a novel complement C5 inhibitor.

More Related Videos

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.3K
Digital Droplet PCR Method for the Quantification of AAV Transduction Efficiency in Murine Retina
09:50

Digital Droplet PCR Method for the Quantification of AAV Transduction Efficiency in Murine Retina

Published on: December 25, 2021

4.6K

Related Experiment Videos

Last Updated: Jul 14, 2025

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

7.7K
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.3K
Digital Droplet PCR Method for the Quantification of AAV Transduction Efficiency in Murine Retina
09:50

Digital Droplet PCR Method for the Quantification of AAV Transduction Efficiency in Murine Retina

Published on: December 25, 2021

4.6K
  • Development involved preclinical studies and extensive clinical trials.
  • Regulatory submissions and reviews were conducted to achieve market approval.

    • Main Results:

    • Avacincaptad pegol demonstrated efficacy in slowing the progression of GA in clinical trials.
    • The drug's safety profile was established through rigorous testing.
    • The culmination of development efforts led to regulatory approval.

    Conclusions:

    • Avacincaptad pegol (IZERVAY™) represents a significant advancement in treating geographic atrophy secondary to age-related macular degeneration.
    • This approval offers a new therapeutic option for patients suffering from this debilitating condition.
    • The successful development underscores the potential of complement C5 inhibition in managing AMD progression.